Posters

Cyclosporine ophthalmic emulsion 0.05% in subjects who experience discomfort while engaging in electronic visual tasking: effect on ocular surface staining and visual function

Poster Details

First Author: K.Stonecipher USA

Co Author(s):    G. Torkildsen   E. McLaurin   L. Villanueva   G. Ousler   D. Hollander        

Abstract Details

Purpose:

To assess the effect of a 6-month course of cyclosporine 0.05% ophthalmic emulsion (Restasis�Â�®, Allergan plc) on ocular surface staining, visual function, and other measures of dry eye in subjects who experience discomfort while engaging in electronic visual tasking.

Setting:

Two general ophthalmology practices in the United States.

Methods:

This open-label, 5-visit clinical study enrolled subjects 18 to 55 years of age, with a history of dry eye, who used electronic devices (computers, tablets, phones) on a daily basis, had a score of 2 or greater on the Ora Calibra�â�„�¢ Ocular Discomfort and 4-Symptom Questionnaire, an Ocular Surface Disease Index (OSDI) score >12, and had presence of corneal staining at the first study visit. Subjects were instructed to administer cyclosporine ophthalmic emulsion 0.05% twice-daily for a period of 6 months. Primary efficacy endpoints were ocular surface staining and visual performance at 6 months.

Results:

Forty-six of 51 subjects completed the study per protocol. Mean age was 46.3�Â�±8.30 and 82% were female. At 6 months, significant reductions in regional fluorescein staining were observed. Notably, central corneal staining decreased by 0.75�Â�±0.66 (P<.0001). Subjects reported significant improvements in visual function measured by OSDI questions: blurred vision (P<.0001), poor vision (P=.0002), night driving (P=.016), working with a computer (P<.0001) and watching television (P<.0001). Schirmer�â�€�™s score (secondary endpoint) was increased by 4.0�Â�±7.13 mm (P=.0004); 32% of subjects had an increase of �â�‰�¥5 mm, and 18% had an increase of �â�‰�¥10 mm.

Conclusions:

After 6 months of treatment with cyclosporine ophthalmic emulsion 0.05%, subjects who engage in electronic visual tasks have improvements in ocular surface staining and visual function.

Financial Disclosure:

is employed by a for-profit company with an interest in the subject of the presentation, research is funded, fully or partially, by a competing company, research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented